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Pan-European data on health-related quality of life (HRQL) in chronic obstructive pulmonary
disease (COPD) are lacking.
This cross-sectional epidemiological study evaluated health status in 1817 COPD patients
from an ‘all-comers’ primary care population in seven European countries (87% stable disease;
13% with current exacerbation) using: St George’s Respiratory Questionnaire-COPD specific
(SGRQ-C), the short form health survey (SF-12) and the Functional Assessment of Chronic
Illness Therapy (FACIT) Fatigue scale.
Mean total score for SGRQ was 44.7  19.4 showing marked impairment of HRQL. Scores
differed little between countries (range 39.2e50.1). Impairment was associated with the
severity of airway obstruction, but within each GOLD stage the variation (SD) was wide [Stage
I: 38.5  19.3 (nZ 223); Stage II: 40.4  18.1 (nZ 868); Stage III: 50.2  18.6 (nZ 551); Stage
IV: 58.6  17.7 (n Z 144)]. Patients suffering an exacerbation had a worse SGRQ score
(54.9  19.3) than those with stable disease (43.3  19.0). The presence of 3 co-morbidities
(CM) was also associated with a significantly worse score (49.9  19.1) vs. 1e2 CM (42.1  19.1)uk (P.W. Jones).
0 Elsevier Ltd. All rights reserved.
58 P.W. Jones et al.or no CM (42.3  18.6). Findings with the SF-12 and FACIT-F results were consistent with those
from the SGRQ-C.
This large observational primary care study shows that health status is significantly impaired
in COPD patients of all severities, even in those with mild airway obstruction. Within each
GOLD stage of severity there is considerable heterogeneity in HRQL impairment among
patients.
(Study number: 111749).
ª 2010 Elsevier Ltd. All rights reserved.Introduction
Chronic obstructive pulmonary disease (COPD) is a leading
cause of morbidity and mortality worldwide resulting in
a significant economic and social burden.1 By 2020, COPD is
estimated to become the fifth most common cause of
morbidity and the third most common cause of death
worldwide.2 Spirometry remains the standard method for
grading COPD severity in international treatment guide-
lines.1,3,4 However, spirometry alone provides insufficient
data on the effect of the disease on patients’ lives.
Many studies have reported impaired health-related
quality of life (HRQL) in patients with COPD5e9 and a poor
HRQL has been shown to be associated with high levels of
dyspnoea,6e8 physical impairment,8 depression and
anxiety,5,8 a poor prognosis in terms of readmission to
hospital10 and death.11 COPD exacerbations have also been
associated with reduced health status, persisting after the
exacerbations12 as has an increased exacerbation
frequency.13 Some patients with severe airway obstruction
may report few symptomswhilst otherswithmild obstruction
report severe symptoms.1 There is evidence of health status
under-estimation by both patients and physicians.1,14 When
grading severity and the burden of the disease, it is now
recognised that patient-reported outcomes provide impor-
tant information that is complementary to lung function
data.15
HRQL assessments may be performed using either
generic or disease-specific questionnaires encompassing
physical, psychological and social factors.16 To our knowl-
edge, the impact of COPD on both aspects of HRQL in
a broadly sampled, multi-national population has not been
previously studied. This cross-sectional, observational study
was undertaken to provide data on the HRQL of a sample of
COPD patients from primary care settings across seven
European countries, using disease-specific and generic
HRQL questionnaires.Methods
Subjects
Eligible subjects were aged 40e80 years with an established
COPD history (minimum six months from diagnosis) and
a known post-bronchodilator forced expiratory volume in
1 s/forced vital capacity (FEV1/FVC) ratio of <70%. All
subjects were either current or ex-smokers with a smoking
history of at least 10 pack years. Exclusion criteria were
asthma or any current respiratory disorder other thanCOPD, and serious, unstable cardiovascular disease.
Recruitment took place between December 2008 and April
2009.
The study was approved by Institutional Review Boards
or Ethics Committees according to local laws and regula-
tions in the respective countries. Written informed consent
was obtained from each subject.
Study design
The study was a cross-sectional, epidemiological, non-
randomised survey, conducted in a primary care setting
in Belgium, France, Germany, Italy, the Netherlands,
Spain and the United Kingdom (UK). Primary care prac-
titioners (PCPs) were identified using local Glax-
oSmithKline contacts or by mass mailing to PCPs
identified from publicly available sources. Patients with
COPD, presenting at PCP practices for any reason and
who fulfilled the entry criteria, were invited to partici-
pate. This paper presents the results for a sub-sample of
patients who were, additionally, aged 30 years at
diagnosis of COPD, had completed at least one HRQL
questionnaire and fulfilled the Global Initiative for
Chronic Obstructive Lung Disease criterion of FEV1/FVC
ratio <70%. In the UK, due to delays in gaining regulatory
approval and therefore a shortened recruitment time, 39
patients (2.1% of the reported population) were
recruited from a wider list of patients who had been
independently pre-identified, in an anonymised manner,
from PCP patient records. They were telephoned by their
PCP to confirm eligibility and willingness to participate.
Demographic information, medical history, previous and
current COPD medications were recorded. Severity by
GOLD stage was calculated retrospectively from the lung
function measurements documented. Information on blood
gas values was not collected and thus patients are classified
into GOLD stages III and IV without respect to this criterion.
Physician-reported disease status (stable disease or pre-
senting with an exacerbation), symptoms (cough, sputum,
dyspnoea), and spirometry (post-bronchodilator FEV1 and
FVC and FEV1/FVC) were also recorded. Spirometry had to
be performed within six months before study entry or
during the single study visit. The history of exacerbations in
the previous 6 months was also recorded, using medical
records and patient-recall as verification. An exacerbation
was defined as a worsening of symptoms that required oral
corticosteroids and/or antibiotics and/or hospitalizations.
Based on the response of the patient, the investigator
scored the patient’s breathlessness using the Medical
Research Council (MRC) Dyspnoea Scale.17
All Comers Population  
(patients with diagnosis of COPD) 
Germany 
PCP=121 
N=2023 
France 
PCP=94 
N=1400
Spain 
PCP=64
N=811 
Belgium
PCP=33
N=394 
Netherlands
PCP=19
N=260 
UK
PCP=14
N=157 
Italy 
PCP=7
N=41
Total N=5086
Eligible Subjects  
(patients fulfilling inclusion/exclusion criteria) 
Germany
N=1232 
France 
N=718 
Spain 
N=519
Belgium
N=297 
Netherlands
N=175 
UK 
N=126 
Italy
N=22 
Total N=3089
Enrolled subjects giving informed consent 
Germany 
N=905 
France 
N=589 
Spain 
N=467 
Belgium 
N=265 
Netherlands
N=154 
UK 
N=126 
Italy 
N=20
Total N=2526
Patients not eligible: N=1997 
Patients not giving informed 
consent: N=469 
CRF not completed: N=94
Age at COPD diagnosis < 30 years: 
N=64 
Smoking <10 pack years: N=28 
Did not complete one questionnaire: N=4
Reported Population2
Germany 
N=621 
France 
N=383 
Spain
N=393
Belgium 
N=199 
Netherlands
N=139 
UK
N=71
Italy
N=11 
Total N=1817
Health Outcomes Population1
Germany 
N=871 
France 
N=573 
Spain 
N=459 
Belgium 
N=242 
Netherlands
N=149 
UK 
N=117 
Italy 
N=19
Total N=2430
FEV1 /FVC < 70% not 
demonstrated: N=613 
Figure 1 Patient flow through survey. PCP represents
number of primary care physicians. 1Health Outcomes Pop-
ulation consisted of patients with: (1) Age at diagnosis of COPD
30 (2) Number of pack years >10, and (3) At least one HRQL
questionnaire completed. 2Reported Population consisted of
the Health Outcomes Population and demonstrating a FEV1/
FVC ratio <70%.
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Patients were asked to complete the following HRQL
questionnaires at the single PCP visit, using validated
translations. The questionnaires were completed after all
other assessments had been conducted.
St George’s respiratory questionnaire e COPD
specific (SGRQ-C)
The SGRQ is a disease-specific HRQL questionnaire18 and in
this survey, the COPD specific version (SGRQ-C) was used.19
It has a total and three component scores for: symptoms,
activity and impacts; each score ranges from 0 (no
impairment) to 100 (worst possible). SGRQ-C scores are
transformed to be fully comparable with SGRQ scores, and
are reported here as SGRQ scores exclusively.19 A differ-
ence of four units in the SGRQ score is considered the
minimum clinically important difference (MCID).20 The
SGRQ-C is designed to assess current health and does not
specify a recall period.20Short form health survey (SF-12)
Generic HRQL was assessed using the SF-12 (version
2).21,22 This has two component summary scores (physical
and mental or PCS-12 and MCS-12), ranging from 0 (worst)
to 100 (best). Scores are normalised so that scores above
or below 50 would be better or worse, respectively, than
the general population. Excluding the first two general
questions, the recall period for the SF-12 is seven days.
The MCID is reported to be a change of 3 units for PCS and
3.5 units for MCS (Quality Metric Inc, private
communication).The functional assessment of chronic illness
therapy (FACIT) fatigue scale
Fatigue was assessed using the generic, FACIT-Fatigue
scale (FACIT-F) (version 4), designed to measure fatigue
intensity and impact on daily life in a general pop-
ulation.23 It assesses tiredness, weakness, and difficulty
conducting usual activities due to fatigue. Recall period is
one week and scores range from 0 to 52, corresponding to
the most and least fatigue, respectively. A change of 3e4
units in the FACIT-F score has been deemed to be the
MCID.24Statistical analysis
The sample size was calculated to ensure a sufficient
sample of patients in all participating countries and
across all levels of COPD severity with the main intention
of providing sufficient accuracy for the comparison of
HRQL scores between stages of COPD severity. Using
SGRQ data from other studies, the smallest acceptable
subgroup sample size was estimated as 120 patients,
pertaining to the subgroup with very severe COPD.
According to the known distribution of disease severity
grades this subgroup covers about 5% of all COPD
patients. This resulted in a total estimated sample size
of approximately 2300 subjects. Based on these
sample sizes and a within-group standard deviation of
18 points of total SGRQ scores, the half-width of the 95%
confidence interval for mean total SGRQ values were
estimated to be less than 3.5 points thus allowing for
reasonable and meaningful descriptive subgroup
comparisons based on 95% confidence intervals of mean
total SGRQ scores. Note, that the minimum important
clinical difference (MCID) of total SGRQ scores is known
to be 4 points.
Descriptive statistics, analysed using Statistical Analysis
Systems version 9.1.3 software (SAS Inc, Cary, USA), were
used to report demographic and baseline characteristics
and distribution of HRQL questionnaire scores and
subgroups split by country, sex, age, COPD status (stable
disease vs. exacerbation), GOLD stage, number of co-
morbidities and cardiovascular (CV) co-morbidities.
Patients with CV co-morbidities were defined as those with
at least one of: myocardial infarction, stroke, heart failure,
treated hypertension, treated angina pectoris or treated
arrhythmia.
Table 1 Demographic and clinical characteristics of COPD patients.
Characteristic GOLD Staginga Reported Population
(N Z 1817)I (N Z 223) II (N Z 868) III (N Z 551) IV (N Z 144)
Male sex, n (%) 144 (64.6) 610 (70.3) 413 (75.0) 122 (84.7) 1305 (71.8)
Age (years), mean (SD) 65.3 (9.7) 65.0 (9.8) 65.0 (9.5) 63.3 (9.5) 64.9 (9.6)
Reason for consultationb, n (%):
Scheduled appointment 102 (45.7) 500 (57.6) 319 (57.9) 78 (54.2) 1006 (55.4)
Prescription refill 77 (34.5) 228 (26.3) 113 (20.5) 30 (20.8) 451 (24.8)
Respiratory reasons 23 (10.3) 97 (11.2) 88 (16.0) 26 (18.1) 236 (13.0)
Non-respiratory reasons 41 (18.4) 139 (16.0) 60 (10.9) 16 (11.1) 262 (14.4)
Duration COPD (years), mean (SD) 8.4 (6.6) 8.8 (6.7) 10.4 (7.5) 10.3 (6.4) 9.4 (7.0)
Pack years, mean (SD) 36.9 (21.2) 39.2 (21.6) 42.4 (27.7) 43.8 (29.6) 40.4 (24.4)
Current smoker, n (%) 100 (44.8) 379 (43.7) 233 (42.3) 52 (36.1) 781 (43.0)
Number of co-morbididties,
Mean (SD) 2.2 (1.7) 2.1 (1.7) 1.9 (1.5) 2.1 (1.6) 2.0 (1.6)
Number of cardiovascular co-morbidities,
mean (SD)
0.8 (0.9) 0.9 (1.0) 1.0 (1.1) 0.9 (1.1) 0.9 (1.0)
Exacerbations on study day, n (%):
Stable disease 204 (91.5) 777 (89.5) 461 (83.7) 110 (76.4) 1580 (87.0)
Exacerbation 19 (8.5) 91 (10.5) 90 (16.3) 34 (23.6) 237 (13.0)
Exacerbations in last 6 months, n (%), requiring:
Antibiotics 117 (52.5) 458 (52.8) 318 (57.7) 93 (64.6) 1005 (55.3)
Oral corticosteroids 66 (29.6) 276 (31.8) 205 (37.2) 70 (48.6) 632 (34.8)
Hospitalisation 15 (6.7) 56 (6.5) 72 (13.1) 31 (21.5) 175 (9.6)
COPD symptoms on study day, n (%)
Cough 165 (74.0) 656 (75.6) 440 (79.9) 125 (86.8) 1405 (77.3)
Sputum 141 (63.2) 556 (64.1) 415 (75.3) 106 (73.6) 1234 (67.9)
Dyspnoea 131 (58.7) 584 (67.3) 453 (82.2) 132 (91.7) 1321 (72.7)
Lung function, mean (SD):
FEV1 (L) 2.4 (0.5) 1.8 (0.4) 1.1 (0.3) 0.7 (0.2) 1.6 (0.6)
FEV1% of predicted 92.2 (11.8) 63.3 (8.3) 40.6 (5.5) 24.1 (4.6) 56.7 (20.1)
MRC dyspnoea scalec, n (%):
1 65 (29.1) 207 (23.8) 55 (10.0) 15 (10.4) 344 (18.9)
2 88 (39.5) 392 (45.2) 180 (32.7) 23 (16.0) 694 (38.2)
3 42 (18.8) 181 (20.9) 166 (30.1) 29 (20.1) 427 (23.5)
4 25 (11.2) 70 (8.1) 125 (22.7) 43 (29.9) 271 (14.9)
5 3 (1.3) 17 (2.0) 24 (4.4) 34 (23.6) 79 (4.3)
MRC Z Medical Research Council; FEV1 Z forced expiratory volume in 1 s. FVC Z forced vital capacity.
a FEV1 (% predicted) is missing for 31 patients due to missing information on height, therefore they are not classifiable into GOLD stages.
b Patients may have reported more than one reason.
c MRC scale: 1: ‘only breathless with strenuous exercise’; 2: ‘breathless when hurrying on level or up a slight hill’; 3: ‘walk slower than
people of same age on the level due to breathlessness or stop for breath when walking on level at own pace’; 4: ‘stop for breath after
walking 100 yards or a few minutes on the level’; 5: ‘Too breathless to leave house or breathless when dressing’.
60 P.W. Jones et al.For testing the relationship between HRQL scores and
GOLD stages, taking country into consideration, analysis of
variance models were applied for all available HRQL scores
with the factors GOLD stage, country and their interaction
term. The test for statistical significance of the latter was
used as a means of assessing the general association
between GOLD stage and HRQL scores. As a global assess-
ment, this test takes account of all patient characteristics
simultaneously (including age, sex, duration of COPD and
co-morbidities). If differences between countries in
patients’ characteristics have a relevant impact on the
relationship between a HRQL score and GOLD stages, it
would be shown as a significant interaction term in the
respective model. All statistical tests were interpreted as
descriptive ones and were performed at the nominal level
of 0.05. Analysis of variance F-tests or two-sample t-testsfor continuous data, or Fisher’s exact tests for categorical
data, were applied respectively.
Results
Study population
A total of 352 PCPs contributed patients to the survey and
identified 5086 patients with COPD from their practices
(Fig. 1). The Health Outcomes Population comprised 2430
patients of which 1817 fulfilled the GOLD criterion by
demonstrating FEV1/FVC <70%. Results for this population
are reported here. FEV1 as percent predicted was not
available for 31 subjects due to missing information on
patients’ height.
Table 2 Health-related quality of life (HRQL) Scores by GOLD stage.
HRQL Questionnaire Severity by GOLD Stagea Reported Population
(N Z 1817)Stage I (N Z 223) Stage II (N Z 868) Stage III (N Z 551) Stage IV (N Z 144)
SGRQb
Total score:
Mean (SD) 38.5 (19.3) 40.4 (18.1) 50.2 (18.6) 58.6 (17.7) 44.7 (19.4)
P25 22.3 26.5 37.3 45.7 29.6
Median 37.5 39.1 50.2 59.8 44.4
P75 52.1 53.1 63.9 73.2 58.9
Symptom score:
Mean (SD) 56.2(24.0) 57.5 (21.6) 66.0 (20.4) 73.7 (16.8) 61.4 (21.9)
P25 37.4 42.9 53.1 61.1 45.9
Median 55.0 56.3 67.9 75.4 61.7
P75 75.4 73.9 83.0 88.1 78.7
Activity score:
Mean (SD) 47.6 (21.8) 51.1 (20.8) 62.1 (20.6) 70.3 (18.8) 55.8 (21.9)
P25 32.9 33.3 50.8 58.6 39.7
Median 52.3 52.4 65.7 72.5 58.6
P75 59.6 65.8 79.6 86.8 72.5
Impacts score:
Mean (SD) 27.8 (19.8) 28.7 (19.0) 38.0 (20.8) 46.6 (20.8) 33.0 (20.7)
P25 11.6 13.5 21.7 31.4 16.0
Median 23.9 24.7 37.1 46.2 30.2
P75 40.8 40.9 52.5 63.8 47.1
SF-12c
PCS:
Mean (SD) 39.8 (8.8) 39.3(8.7) 35.7 (8.7) 31.7 (8.6) 37.7 (9.1)
P25 33.3 32.7 29.5 25.9 30.8
Median 39.8 39.8 35.4 30.5 37.7
P75 46.5 45.6 42.0 37.4 44.5
MCS:
Mean (SD) 47.4 (11.8) 47.9 (11.3) 47.0 (12.0) 43.7 (12.9) 47.2 (11.8)
P25 38.2 39.3 38.7 33.4 38.7
Median 48.0 48.7 47.8 42.3 48.0
P75 58.4 57.0 56.8 53.2 57.0
FACIT-Fd
Mean (SD) 36.4 (11.0) 36.3 (10.8) 32.5(12.1) 28.7 (12.1) 34.5 (11.6)
P25 29.5 29.0 23.0 20.0 26.0
Median 38.0 39.0 33.5 28.0 37.0
P75 46.0 45.0 43.0 37.0 44.0
P25Z 25th percentile; P75Z 75th percentile; SGRQZSt George’s Respiratory Questionnaire; SF-12Z Short Form health survey; FACIT-
FZFunctional Assessment of Chronic Illness Therapy (FACIT) Fatigue scale; PCSZ Physical component score; MCSZ Mental component
score.
a FEV1 (% predicted) is missing for 31 patients due to missing information on height, therefore they are not included in this table.
b Reported as SGRQ scores following transformation from SGRQ-C scores; SGRQ total score: a lower score represents a better QoL.
c SF-12 scores: a higher score represents a better QoL.
d FACIT-fatigue scores: higher score indicates less fatigue.
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Demographic and clinical characteristics of study patients
are presented by GOLD stage (Table 1). Approximately
three quarters of patients were male. The mean age was 65
years and mean duration of COPD was 9 years. The mean
FEV1 was 1.6L (57% of predicted). Over 40% of all patients
were current smokers with mean 40 smoking pack years.
Over half of the patients in GOLD Stages II to IV had visited
the PCP for a scheduled appointment on the study visit day.
The proportion of patients attending for respiratory reasonswas higher in those with more severe obstruction (10% of
GOLD Stage I vs. 18% of GOLD Stage IV, most presenting with
an exacerbation). A total of 13% of patients had an exac-
erbation at the study visit. In the previous six months, 10%
of all patients had been hospitalised due to an exacerbation
(Stage I: 6.7%, Stage II: 6.5%, Stage III: 13.1%, Stage IV:
21.5%) (Table 1). For exacerbations requiring antibiotics or
oral corticosteroids there was no difference in numbers
reported between GOLD Stages I and II. A high level of
symptoms was reported even in patients in GOLD Stage I
(cough 74.0%, sputum production 63.2% and dyspnoea
Figure 2 HRQL scores by COPD status on study day (mean + SD) (stable disease versus exacerbation) a) SGRQ total score by COPD
status b) SF-12 component scores by COPD status c) FACIT-Fatigue score by COPD status.
62 P.W. Jones et al.58.7%), and increased symptoms were observed with more
severe disease (Table 1).
Co-morbidities were frequent: hypertension 53%, hyper-
cholesterolaemia 41%, osteoarthritis 26%, sleep disorder
25%, heartburn 21%, diabetes 19%, depression 17%, anxiety
15%. There was no difference in the mean number of co-
morbidities reported by GOLD Stages (Table 1). In total, 89%
of patients were receiving COPD treatment: inhaled corti-
costeroid/long-acting b2-agonist (ICS/LABA) combination
(55%), long-acting anticholinergics (41%), short-acting
b2-agonists (38%), short-acting anticholinergics (20%), LABA
(17%) and ICS (12%). Smoking cessation treatment was being
received by 4.4% of current smokers.
HRQL measures
All the HRQL questionnaires showed significant impairment
across all levels of airway obstruction, even in patients with
mild disease (Table 2). The differences between Stage I and II
were less than the MCID with all questionnaires; by contrast
differences between Stage II-III and Stage III-IV exceeded the
MCIDs (with the single exception of SF-12 MCS). Within each
severity group, there was considerable heterogeneity in
impairment as evidenced by wide standard deviations.
Demographic factors had little effect on scores;
although on the SF-12 MCS, males scored better than
females: 48.4 (95% CI 47.7, 49.0) vs. 44.3 (95% CI 43.3,
45.4). Significant differences (smaller than the MCID) were
noted for FACIT-F scores: males 35.0 (95% CI 34.4, 35.6) vs.
females 33.1 (95% CI 32.0, 34.1), SF-12 PCS scores: younger
(65 years) 38.6 (95% CI 38.0, 39.2) vs. older 36.8 (95% CI
36.2, 37.4); SF-12 MCS younger: 46.0 (95% CI 45.2, 46.8) vs.
older 48.4 (95% CI 47.7, 49.2).
Patients with stable disease showed statistically and
clinically better HRQL scores and less fatigue than those
suffering an exacerbation (Fig. 2). The presence of 3
reported co-morbidities (CM) was associated with worse
HRQLcomparedwith<3co-morbidities (Fig. 3). Patientswith
cardiovascular co-morbidities (CV-CM) reported worse SGRQ
scores (45.8  19.5) than those without (43.2  19.2),
p< 0.01, but the difference was less than theMCID (Fig. 3). Asimilar picture was seen with the SF-12 PCS: no CV-CM
38.9  9.2, presence of CV-CM 36.8  8.8, p < 0.001.
HRQL by country
The average HRQL scores showed some inter-country varia-
tion. For example, the mean SGRQ score in The Netherlands
differedbymore than theMCID fromthemeanof all countries
(Fig. 4a). Similarly there was also some variation in SF-12 and
FACIT-F scores (Fig. 4b and c). MRC dyspnoea grades varied to
a similar degree between countries for all grades.
These variations in HRQL scores appear to be due to
differences in patient characteristics (i.e. age, sex, duration
of disease, disease severity and co-morbidities) between the
sub-samples per country, but not due to different relation-
ships betweenHRQL scores andGOLDstages across countries.
Thiswas shownby thenon-significant interaction terms in the
linear models relating country and GOLD stage on HRQL
scores. Thiswas seenwith all HRQLmeasures: total SGRQ, SF-
12 MCS, SF-12 PCS, and FACIT.Discussion
To our knowledge, this is the first large-scale study to use
disease-specific and generic HRQL questionnaires to survey
patients of all levels of COPD severity in primary care. HRQL
was markedly impaired across all levels of severity of
airway obstruction. A comparison of SGRQ scores from our
study with those from the two population-based COPD
studies, IBERPOC25 and EPI-SCAN,26 which included control
subjects and patients classified as GOLD Stage ‘0’, support
our findings that patients with all severities had abnormal
SGRQ scores, even those with mild disease. The most
notable observations in our study are the marked impair-
ments and small differences between patients in GOLD
Stages I and II, whether assessed using generic or disease-
specific HRQL questionnaires. The most likely explanation
for our finding of poor health being associated with only
mild-moderate obstructions is that patients with few
symptoms are not detected and consequently not
Figure 3 HRQL scores by number of co-morbidities and by cardiovascular co-morbidities
a) SGRQ total score by number of co-morbidities (mean þ SD)
b) SF-12 component scores by number of co-morbidities (mean þ SD)
c) FACIT-Fatigue score by number of co-morbidities (mean þ SD)
d) SGRQ total score by cardiovascular co-morbidities (present1 or absent) (mean þ SD). CV Z cardiovascular. (1defined as the
patient having myocardial infarction, stroke or heart failure or patient being treated for hypertension, angina pectoris or
arrhythmia)
e) SF-12 component scores by cardiovascular co-morbidities (present1 or absent) (mean þ SD). CV Z cardiovascular;
PCSZ physical component score; MCSZ mental component score. (1defined as the patient having myocardial infarction, stroke or
heart failure or patient being treated for hypertension, angina pectoris or arrhythmia)
f) FACIT-Fatigue by cardiovascular co-morbidities (present1 or absent) (mean þ SD). (1defined as the patient having myocardial
infarction, stroke or heart failure or patient being treated for hypertension, angina pectoris or arrhythmia)
No p-value shown indicates ’statistical non-significance’.
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GOLD staging when applied to all individuals with COPD in
a population, whether diagnosed or not, but they do
question the utility of GOLD staging alone (particularly I
and II) for judging clinical severity in patients with diag-
nosed COPD, and suggest that burden of disease assess-
ments provide additional complementary information.
Setting our findings into a broader context, the SGRQ
scores from our population are comparable to baseline
values from the UPLIFT study.27 Our study did include
data from a small number of patients who were expe-
riencing an exacerbation whereas most other studies
excluded recently exacerbated patients.28,29 However,even patients with stable COPD and mild obstruction in
our study reported SGRQ scores considerably higher
than the upper limit of approximately 7 units expected
in a healthy population.25 SF-12 scores, particularly the
physical component score, were lower (i.e. worse) than
those obtained in a recent sample of 60e69 year olds
from the general population in The Netherlands, in
whom the mean MCS was 51.3 and mean PCS was
50.9.30
Our survey allowed us to compare SF-12 scores in COPD
with scores in other chronic diseases. Xie et al. showed
significant impairment in SF-12 scores in a US population of
patients with coronary heart disease compared with a non-
Figure 4 HRQL scores by country (Italy excluded due to small patient numbers)
a) SGRQ total score by country1, b) SF-12 component scores by country1, c) FACIT-Fatigue score by country1 (1drepresents mean
score for all countries; - - - - - represents  MCID).
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coronary heart disease were comparable to our COPD pop-
ulation.31 The SF-12 was derived from the SF-36 with which
the scores are closely comparable.22 In a study of patients
with chronic conditions in six European countries, Japan and
the USA, individuals reporting arthritis, congestive heart
failure and chronic lung disease showed the highest impact
on the SF-36, scoring around 47.5 for PCS, compared with
51.9 in respondentswith no reported conditions. The score of
37.7 recorded for SF-12 PCS in our study indicates that
primary care COPD patients suffer at least as much poor
health as patients with other chronic conditions.32
Fatigue was prominent, even in GOLD Stage I patients.
The data were consistent across countries. The FACIT-F
scores were well below (i.e. worse than) the lower limit of
43 assessed in a US healthy population.33 Data on COPD-
related fatigue are scarce and to our knowledge, this is the
largest set of data analysing FACIT scores in COPD, although
a recent, smaller study also reported significantly greater
fatigue in COPD patients during exacerbations.34
The symptom pattern differed with the degree of airway
obstruction; cough was the prominent symptom in mild
obstruction whereas dyspnoea was more frequently reportedwith severe and very severe obstruction. However, disability
due to breathlessness was common even in patients with
mild-moderate disease. The MRC dyspnoea scores showed
that 70% of patients with mild disease and 74% of those with
moderate obstruction experienced limitations in routine
activities such as walking to the shops or keeping pace with
their peers. The lack of complaint about cough in more
severe disease may indicate that patients are overwhelmed
by breathlessness rather than cough no longer being trou-
blesome. The prominence of cough in mild disease could be
an important indicator to PCPs to consider a diagnosis of
COPD in patients presenting with persistent cough.
On all measures, there was an association between the
presence of three or more reported co-morbidities and
impaired HRQL. As might be expected, a step increase in
co-morbidity count was associated with worsening of the
generic SF-12 PCS score. By contrast, the SGRQ scores were
almost identical in patients with under three co-morbid-
ities, suggesting that the disease-specific SGRQ is not
influenced by the presence of low levels of co-morbidity.
There was a large step worsening in SGRQ in patients with
3 co-morbidities, which accords with the observation that
more severe COPD is associated with a greater number of
Health-related QoL in COPD patients in primary care, Europe 65co-morbidities.35 In our own data, there was no relationship
between mean number of co-morbidities and GOLD Stage.
The population recruited to this study was not a random
sample of COPD patients within primary care; they were
patients attending for a consultation. This may have biased
the sample towards a more symptomatic group, explaining
the high rate of reported exacerbations over the previous
six months. New patients often consult because of a severe
or persistent ‘chest infection’ (we noted over 50% of GOLD I
and II patients required antibiotics for an exacerbation in
the preceding six months). However, this is unlikely to have
significantly influenced our study since the mean duration
of COPD diagnosis was over 6 years, even in mild patients.
Surprisingly, 7% of GOLD Stage I and II patients had been
hospitalised for an exacerbation over the preceding 6
months. Scheduled appointment and prescription refill
accounted for over three quarters of consultations sug-
gesting that patients were being actively managed for
chronic illness.
One of the criticisms of this study may be that the
recruited patients were not fully representative of the
whole COPD population. The method of patient recruitment
meant that only patients with known diagnosed COPD were
sampled. However, the sampling method did identify
patients who reflect those seen in every-day practice in
primary care across Europe, so the population is represen-
tative in that respect. It is believed that many patients with
mild disease remain undiagnosed, so these patients would
not have been included in this survey. Another limitation of
the study is that countries were chosen on the basis of
representing large COPD populations, so not all European
countries are reflected in the dataset. Differences existed
in the distribution of patient characteristics including COPD
severity and consequently HRQL scores between countries
in our sample. These are most likely caused by the different
socio-demographic factors, differences between health-
care systems and therefore, the slightly different roles of
PCPs in providing COPD care. In consequence, the mix of
patients in terms of COPD severity, and some other char-
acteristics, routinely showing up at their PCP, is likely to
vary between countries. However, the relationship
between HRQL impairment and GOLD Staging showed very
similar patterns across countries, whether assessed in
terms of MRC grade, or generic or disease-specific HRQL
scores e suggesting that our findings may be applicable at
the pooled (European) level, and generalised to other
countries and healthcare systems.
In conclusion, this large observational European study
confirms that health status is significantly impaired in COPD
patients across all severities. We observed marked impair-
ment in HRQL even in milder disease and there was little
difference in the degree of impairment between GOLD Stage
I and II patients. There was very wide variation in the
patients’ HRQL within each GOLD Stage. We conclude that
a measurement of HRQL should be routinely included in the
assessment andmonitoring of COPD patients in primary care.Conflict of interest statement
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